Versailles

Versailles Biopharma was a clinical-stage biotechnology company focused on developing innovative topical treatments for inflammatory skin diseases and chronic pruritus. Founded by a team of experienced dermatology executives, the company's lead program, VBS-01, was designed to address the significant unmet need in patients suffering from persistent itch. In 2019, the company was acquired by MC2 Therapeutics, which integrated Versailles' pipeline into its own dermatology portfolio. The acquisition expanded MC2's reach into the pruritus market, leveraging Versailles' expertise in topical drug development. The lead asset, now known as MC2-25, represents a novel approach to treating the sensory components of skin disease.